Sentence examples for benefit of adding chemotherapy from inspiring English sources

We think that if such patients are on HAART, their tolerance to chemo-radiotherapy will be better and the additional benefit of adding chemotherapy is desirable.

The 21-gene recurrence score has been shown to be both prognostic and predictive of the benefit of adding chemotherapy to tamoxifen.

The benefit of adding chemotherapy to radiotherapy was seen regardless of age, histology and grade, but appeared to be lower in patients with more advanced tumours.

Adult brainstem gliomas present with a wide variety of neurological symptoms and postoperative radiation remains the cornerstone of therapy with no proven benefit of adding chemotherapy.

The anticipated benefit of adding chemotherapy to TACE assumes that hepatocellular is sufficiently chemosensitive to improve survival over and above that obtained by TAE alone.

Some retrospective studies in recent years also have showed the benefit of adding chemotherapy to radiation in patients with intermediate-risk factors and the levels of all toxicities were acceptable [ 17- 20].

Two studies evaluating the benefits of adding chemotherapy to radiation therapy yielded conflicting results, but a pooled analysis suggested a benefit from concurrent chemoradiotherapy compared with radiotherapy alone.

Are there patient-specific factors other than hormonal status that predict benefit from ZA? Do the benefits of adding ZA to endocrine therapy in postmenopausal women equal the benefits of adding chemotherapy for these women?

According to a recent meta-analysis showing the benefits of adding chemotherapy after CRC in case of lymph node metastases, patients with lymph node metastases could be good candidates for this regimen.

These data are of particular relevance, as two trials included in a recent meta-analysis (Lukka et al, 2002; Green et al, 2005; Chemoradiotherapy for Cervical Cancer Meta-analysis CCCMACoration (CCCMAC), 2010) showed greater benefits of adding chemotherapy after CRC, with an absolute improvement of 19% at 5 years.

To date, the Recurrence Score assay is the only one shown to predict the likelihood of chemotherapy benefit (i.e., which patients are likely to benefit from adding chemotherapy to endocrine therapy and which are unlikely to derive benefit) [ 2, 4].